XNAS
ENSC
Market cap6mUSD
Oct 08, Last price
0.46USD
1D
6.66%
1Q
69.69%
IPO
-100.00%
Name
Ensysce Biosciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
32.06%
Rev. gr., 5y
5.21%
Revenues
0
-100.00%
Net income
-10m
L+27.40%
CFO
-8m
L-100.00%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Key people
Jeffrey Millard
Chief Operating Officer · since 2019
David Humphrey
Chief Financial Officer, Treasurer, Secretary · since 2021
Geoffrey Birkett
Chief Commercial Officer · since 2018
Linda Pestano
Chief Development Officer · since 2021
William Schmidt
Chief Medical Officer · since 2016
Lynn Kirkpatrick
President, Chief Executive Officer, Director · since 2009
Andrew Benton
Independent Director · since 2019
William Chang
Independent Director · since 2016
Adam Levin
Independent Director · since 2021
Steve Martin
Independent Director · since 2020
Lee Rauch
Independent Director · since 2022
Curtis Rosebraugh
Independent Director · since 2021
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||